AMRN - Amarin Corporation plc
收市後：
| 前收市價 | 1.2400 |
| 開市 | 1.2200 |
| 買盤 | 0.0000 x 4000 |
| 賣出價 | 0.0000 x 28000 |
| 今日波幅 | 1.2200 - 1.3100 |
| 52 週波幅 | 1.0400 - 2.2300 |
| 成交量 | |
| 平均成交量 | 2,751,531 |
| 市值 | 513.803M |
| Beta 值 (5 年，每月) | 1.79 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.2300 |
| 業績公佈日 | 2023年5月03日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 2.13 |
InvestorPlace3 Biotech Stocks to Avoid Like the Plague
Biotech stocks have gotten caught up in the broader technology sector sell-off. The benchmark iShares Biotechnology ETF (NYSEARCA:IBB) has fallen from a peak of $175 in 2021 to just $130 today. There are few signs of a biotech stock bubble at this point. That said, even with the sector at an overall discount, that’s not an all-clear for the whole sector. Many of the worst biotech stocks either have a drug prospect that is unlikely to get FDA approval or one that simply never garners much commerc
BenzingaAmarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome
Amarin Corporation plc (NASDAQ: AMRN) announced a new analysis from the Vascepa/Vazkepa (icosapent ethyl) cardiovascular outcomes REDUCE-IT study. The study exhibited the effectiveness of Vascepa/Vazkepa in patients with the recent acute coronary syndrome. The post-hoc analysis showed that icosapent ethyl (IPE) substantially and significantly reduced the risk of first and total ischemic events by 37% and 36%, respectively, in patients with the recent acute coronary syndrome (ACS) without increas
Insider MonkeyAmarin Corporation plc (NASDAQ:AMRN) Q4 2022 Earnings Call Transcript
Amarin Corporation plc (NASDAQ:AMRN) Q4 2022 Earnings Call Transcript March 1, 2023 Operator: Welcome to Amarin Corporation’s Conference Call to Discuss its Fourth Quarter and Full Year 2022 Financial Results and Operational Update. I would now like to turn the conference call over to Lisa DeFrancesco, Senior Vice President, Investor Relations and Corporate Affairs at […]
InvestorPlace3 Penny Stocks to Sell in January Before They Peter Out
The changing of the calendar has brought a new sentiment to Wall Street. Many of 2022’s biggest losers, such as meme stocks, SPACs and penny stocks, are suddenly enjoying strong rallies once again. With the Federal Reserve looking like it may stop hiking rates within the next few months, some optimism is returning. However, this improving mood isn’t a green light to buy all depressed stocks indiscriminately. Many firms still face pressing challenges in terms of validating their business model, g
BenzingaAmarin Calls Activist Investor, Largest Shareholder Sarissa's Statement 'Inaccurate, Misleading'
Amarin Corporation Plc (NASDAQ: AMRN) reacted to its largest shareholder, Sarissa Capital Management, which said Amarin's recent board refreshment put "no shareholder representatives on the board." Sarissa said in its statement Wednesday that Amarin "has repeatedly overpromised and underdelivered," with the European launch being delayed and reimbursement in Germany appearing to be imperiled. Amarin described Sarissa's published statement as "inaccurate and misleading." The drugmaker said its boa
BenzingaAmarin Touts Positive Data For Its Heart Disease Drug In Current/Former Smokers
Amarin Corporation plc (NASDAQ: AMRN) announced that new REDUCE-IT data show that Vascepa/Vazkepa (icosapent ethyl) significantly reduced cardiovascular (CV) events in patients with a history of smoking. In this post hoc exploratory analysis, icosapent ethyl (IPE) treatment significantly reduced the risk of first and total primary composite events in current/former smokers by 23% and in former smokers by 29%, compared to the placebo. Related: Amarin's New Vascepa Data Shows Significant Reduction
BenzingaAmarin's New Vascepa Data Shows Significant Reduction In Heart Attack Subtypes
New data shows that Amarin Corporation plc's (NASDAQ: AMRN) Vascepa/Vazkepa (icosapent ethyl) significantly reduced ST-segment and non-ST elevation myocardial infarction (NSTEMI) and other MI subtypes in patients with cardiovascular disease or diabetes with risk factors. The REDUCE-IT study data presented show STEMI was significantly reduced by 40% following treatment with icosapent ethyl (IPE) compared to placebo. IPE also significantly reduced NSTEMI by 27%. Related: Amarin Still Suspends FY22
InvestorPlace7 F-Rated Growth Stocks to Sell Before Q4
It’s probably high time to look at your portfolio and see which growth stocks to sell. It has been a disappointing year on Wall Street, to say the least. In 2021, the major indices were up anywhere from 19.5% to 26.9%. Not too shabby. But so far this year, we’ve not had any such luck. The Dow Jones Industrial Average is down 9.3%; the S&P 500 dropped by 13%, and the tech-heavy Nasdaq composite is down 20.5%. All that is despite a decent rally over the last several weeks. Tools like my Portfolio
BenzingaAmarin Still Suspends FY22 Guidance On Generic Challenges
Amarin Corporation plc (NASDAQ: AMRN) continues suspending 2022 revenue guidance citing the ongoing global impact of COVID-19, the uncertainty resulting from the impact of generic IPE availability in the U.S., and challenges for most drugs seeking market access in Europe. "In the second quarter of 2022, we made important progress on our long-term growth strategy. Our achievements give us confidence in the direction of and opportunities for Amarin during the remainder of 2022 and into 2023," said
Insider Monkey15 Best Penny Stocks To Invest In
In this article, we discuss the 15 best penny stocks to invest in. If you want to skip our analysis of these stocks, go directly to the 5 Best Penny Stocks To Invest In. The US equity market has been volatile since the start of 2022. The Dow 30 Index extended an eight-week consecutive losing […]